Tennessee-Based Veteran-Owned Start-Up to Develop New COVID-19 Screening Method

Newswise — WASHINGTON – As people begin to return to the workplace and in-person operations prepare to resume, facility managers are challenged to employ point-of-entry screening methods that are robust, non-invasive, non-disruptive, and preserve privacy. To address this challenge, the Department of Homeland Security (DHS) Science and Technology Directorate (S&T) awarded $199,653 in Phase 1 funding to Farmspace Systems, LLC, a veteran-owned start-up based in Alamo, Tenn., to enhance its COVID Finder technology, a non-thermal detection COVID-19 screening method.

“We know that using thermal detection, or temperature checks, is a stop gap solution. There isn’t a way to effectively detect the virus in individuals in large volume,” said Melissa Oh, managing director of S&T’s Silicon Valley Innovation Program (SVIP). “Exploring this technology will bolster DHS efforts to safely bring back our valued workforce.” SVIP awarded the funds under the Emerging Needs: COVID-19 Response & Future Mitigation solicitation.

The Farmspace COVID Finder team was formed in May 2020 for the purpose of developing a fast, accurate, and non-invasive COVID-19 screening for asymptomatic and pre-symptomatic viral carriers. Farmspace’s proposed solution entails a COVID Finder Point-of-Passage portal designed to capture and identify real-time images of viruses in exhaled breath using artificial intelligence and disinfect the booth between occupants with ultraviolet light. Phase 1 of this project will establish a framework for using images from breath to diagnose a plethora of infectious, inflammatory, and malignant diseases.

“Based on early analysis, the emerging ‘solution of choice’ for workplace screening was febrile (fever) scanning.  However, better alternatives were always known to be necessary,” said Kevin Grottle, DHS S&T program manager. “This SVIP topic was structured to determine if there were any pre-market technologies that match the ‘ease’ of fever scanning while overcoming its limitations. The Farmspace approach may provide both.”

The potential long-term value of COVID Finder is its ability to adapt screening rapidly to meet the current pandemic screening challenges, as well as possible viral outbreaks in the future.

About SVIP

SVIP is one of S&T’s programs and tools to fund innovation and work with private sector partners to advance homeland security solutions. Companies participating in SVIP are eligible for up to $800,000 of non-dilutive funding over four phases to develop and adapt commercial technologies for homeland security use cases.

For more information on current and future SVIP solicitations, visit https://www.dhs.gov/science-and-technology/svip or contact [email protected].

About S&T

To learn more about S&T response efforts to COVID-19 across the Directorate, please visit S&T Support to the COVID-19 Response.

For more information about S&T’s innovation programs and tools, visit https://www.dhs.gov/science-and-technology/work-with-st.




Filters close

Showing results

110 of 5636
Released: 13-May-2021 7:05 PM EDT
FLCCC Statement on the Irregular Actions of Public Health Agencies & the Disinformation Campaign Against Ivermectin
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

FLCCC Alliance calls for whistleblower to step forward from within WHO, the FDA, the NIH, Merck, or Unitaid to counter this misrepresentation

Newswise: shutterstock_1724336896.jpg
Released: 13-May-2021 12:55 PM EDT
Kreuter receives $1.9 million in grants to increase vaccinations in St. Louis
Washington University in St. Louis

Matthew Kreuter, the Kahn Family Professor of Public Health at the Brown School, has received $1.9 million in grants to help increase COVID-19 vaccinations among Blacks in St. Louis City and County.

Released: 13-May-2021 11:35 AM EDT
COVID-19 mRNA Vaccines are Immunogenic in Pregnant and Lactating Women, Including Against Viral Variants
Beth Israel Deaconess Medical Center

In a new study from Beth Israel Deaconess Medical Center researchers evaluated the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women who received either the Pfizer or Moderna COVID-19 vaccines. They found that both vaccines triggered immune responses in pregnant and lactating women.

Released: 13-May-2021 10:30 AM EDT
Pandemic stigma: Foreigners, doctors wrongly targeted for COVID-19 spread in India
Monash University

The Indian public blamed foreigners, minority groups and doctors for the rapid spread of COVID-19 across the country during the first wave, due to misinformation, rumour and long-held discriminatory beliefs, according to an international study led by Monash University.

Released: 13-May-2021 9:00 AM EDT
28 Community Programs Receive Grants Through Penn Medicine CAREs Program
Perelman School of Medicine at the University of Pennsylvania

Penn Medicine CAREs awarded grants to 28 projects, many of which aim to fill vast needs in the community created by the COVID-19 pandemic, while others seek to improve diversity, equity, and inclusion.

Released: 13-May-2021 9:00 AM EDT
How to Win Over Vaccine Skeptics: Live Expert Panel for May 20, 3pm ET
Newswise

How to Win Over Vaccine Skeptics: Live Expert Panel for May 20, 3pm ET

Released: 13-May-2021 8:00 AM EDT
Dental procedures during pandemic are no riskier than a drink of water
Ohio State University

A new study’s findings dispel the misconception that patients and providers are at high risk of catching COVID-19 at the dentist’s office.

Newswise:Video Embedded lung-damage-not-the-culprit-for-post-covid-exercise-limitations
VIDEO
Released: 13-May-2021 7:00 AM EDT
Lung Damage Not the Culprit for Post-COVID Exercise Limitations
American Physiological Society (APS)

A new study suggests the lungs may not be the main factor that reduce exercise ability in people recovering from severe COVID-19. Anemia and muscle dysfunction also play a role. The study is published ahead of print in the Journal of Applied Physiology. It was chosen as an APSselect article for May.


Showing results

110 of 5636

close
2.34571